Brief: Ventyx Biosciences Q3 Operating Expenses USD 57.951 Million
09/11/2023 21:01
Nov 09 (Reuters) - Ventyx Biosciences Q3 net income USD -54.027 million
Recent news on Ventyx Biosciences
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (updated)
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026
Deals of the day-Mergers and acquisitions